1. Broncho‐Vaxom® (OM‐85 BV) soluble components stimulate sinonasal innate immunity
- Author
-
Triantafillou, Vasiliki, Workman, Alan D, Patel, Neil N, Maina, Ivy W, Tong, Charles CL, Kuan, Edward C, Kennedy, David W, Palmer, James N, Adappa, Nithin D, Waizel‐Haiat, Salomon, and Cohen, Noam A
- Subjects
Medical Physiology ,Biomedical and Clinical Sciences ,Infectious Diseases ,Lung ,Nutrition ,Good Health and Well Being ,Adjuvants ,Immunologic ,Cell Extracts ,Cells ,Cultured ,Cilia ,Epithelial Cells ,Humans ,Immunity ,Innate ,Nasal Mucosa ,Nitric Oxide ,sinusitis ,ciliary motility ,therapeutics ,immunotherapy ,innate immunity ,rhinosinusitis ,Immunology ,Clinical sciences - Abstract
BackgroundBroncho-Vaxom® (OM-85 BV) is an extract of infectious respiratory bacteria that is used as an immunostimulant outside of the United States for the prevention and treatment of bronchitis and rhinosinusitis. Prior studies have shown that use of OM-85 BV is associated with reduction in frequency of respiratory infection and decreased duration of antibiotic usage. However, the effects of OM-85 BV on respiratory mucosal innate immunity are unknown.MethodsHuman sinonasal epithelial cells were grown at an air-liquid interface (ALI). Ciliary beat frequency (CBF) and nitric oxide (NO) production in response to stimulation with OM-85 BV was measured in vitro. Pharmacologic inhibitors of bitter taste receptor (T2R) signaling were used to determine if this pathway was taste-receptor-mediated.ResultsApical application of OM-85 BV resulted in an NO-mediated increase in CBF (p
- Published
- 2019